{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stelara&page=2", "query": { "intervention": "Stelara", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stelara&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T00:41:03.573Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01645280", "title": "A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Placebo + methotrexate (MTX) (Group 1)", "type": "DRUG" }, { "name": "Ustekinumab + MTX (Group 2)", "type": "DRUG" }, { "name": "Ustekinumab + MTX (Group 3)", "type": "DRUG" }, { "name": "CNTO 1959 + MTX (Group 4)", "type": "DRUG" }, { "name": "CNTO 1959 + MTX (Group 5)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 274, "start_date": "2012-08", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-05-12", "last_synced_at": "2026-09-22T00:41:03.573Z", "location_count": 3, "location_summary": "Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri", "locations": [ { "city": "Palm Harbor", "state": "Florida" }, { "city": "Rock Island", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01645280" }, { "nct_id": "NCT05535738", "title": "Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Skin Inflammation", "Allergic Contact Dermatitis" ], "interventions": [ { "name": "Squaric Acid Dibutyl Ester", "type": "DRUG" }, { "name": "Known patch test allergens", "type": "OTHER" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Canakinumab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Triamcinolone Acetonide", "type": "DRUG" }, { "name": "Betamethasone Valerate", "type": "DRUG" }, { "name": "Fluticasone Propionate", "type": "DRUG" }, { "name": "Microneedle", "type": "DEVICE" }, { "name": "Suction blistering", "type": "DEVICE" }, { "name": "Skin punch biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "DEVICE", "PROCEDURE" ], "sponsor": "Wei-Che Ko", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2022-11-15", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-09-22T00:41:03.573Z", "location_count": 1, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05535738" }, { "nct_id": "NCT02955147", "title": "Ustekinumab for the Treatment of Giant Cell Arteritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Giant Cell Arteritis", "Temporal Arteritis", "Horton's Disease" ], "interventions": [ { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 13, "start_date": "2016-12-01", "completion_date": "2019-09-19", "has_results": true, "last_update_posted_date": "2020-06-12", "last_synced_at": "2026-09-22T00:41:03.573Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02955147" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-12-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-22T00:41:03.573Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT05320159", "title": "Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 17743, "start_date": "2021-02-03", "completion_date": "2021-03-31", "has_results": false, "last_update_posted_date": "2022-07-01", "last_synced_at": "2026-09-22T00:41:03.573Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05320159" }, { "nct_id": "NCT01806662", "title": "Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 32, "start_date": "2013-03", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2018-03-14", "last_synced_at": "2026-09-22T00:41:03.573Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01806662" }, { "nct_id": "NCT04524611", "title": "Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease (CD)" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 527, "start_date": "2020-09-30", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-22T00:41:03.573Z", "location_count": 72, "location_summary": "Chandler, Arizona • Coronado, California • Irvine, California + 62 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04524611" }, { "nct_id": "NCT04505410", "title": "Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "A plant based high fiber diet that mimics fasting (\"FMD\") plus advanced therapy", "type": "OTHER" }, { "name": "Advanced therapy only without dietary intervention", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2020-09-18", "completion_date": "2023-12-07", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-09-22T00:41:03.573Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505410" }, { "nct_id": "NCT00955279", "title": "A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoidosis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 173, "start_date": "2009-11", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-07-17", "last_synced_at": "2026-09-22T00:41:03.573Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00955279" }, { "nct_id": "NCT02156375", "title": "A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 140, "start_date": "2014-05", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2016-03-22", "last_synced_at": "2026-09-22T00:41:03.573Z", "location_count": 3, "location_summary": "Tempe, Arizona • Lincoln, Nebraska • Neptune City, New Jersey", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02156375" } ] }